Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.81 |
| ▸ | STAT6 | P42226 | 2/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.33 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | MMP2 | P08253 | 8/20 | 0.32 |
| ▸ | MMP3 | P08254 | 7/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taltobulin SCHEMBL6799555 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL57122 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL6670481 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL13751415 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL4378011 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL58356 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL13751409 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL58672 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL13848320 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL16176425 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20090264487-A1 | HEMIASTERLIN ANALOGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-10-22 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7579323-B1 | Analogs of hemiasterlin wherein the indole moiety of hemiasterlin has been deleted or replaced demonstrate potent anti-mitotic and cytotoxic activity; may be useful in treatment of colon, breast, lung cancers | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-08-25 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885STAT6 4739/4885ADAM17 1814/4885 |
| US-20090264487-A1 | HEMIASTERLIN ANALOGS | NUMA1, CYP11A1, PDS5A | TUBB1 168/4885STAT6 4837/4885ADAM17 2504/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | TUBB1 1668/4885STAT6 4810/4885ADAM17 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.